DK0881891T3 - Mandigt præventionsimplantat - Google Patents

Mandigt præventionsimplantat

Info

Publication number
DK0881891T3
DK0881891T3 DK97907788T DK97907788T DK0881891T3 DK 0881891 T3 DK0881891 T3 DK 0881891T3 DK 97907788 T DK97907788 T DK 97907788T DK 97907788 T DK97907788 T DK 97907788T DK 0881891 T3 DK0881891 T3 DK 0881891T3
Authority
DK
Denmark
Prior art keywords
implant
male contraceptive
androgen
vinyl acetate
well
Prior art date
Application number
DK97907788T
Other languages
Danish (da)
English (en)
Inventor
Saleh I Saleh
Alfred J Moo-Young
Original Assignee
Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc filed Critical Population Council Inc
Application granted granted Critical
Publication of DK0881891T3 publication Critical patent/DK0881891T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Materials For Medical Uses (AREA)
  • Coupling Device And Connection With Printed Circuit (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
DK97907788T 1996-02-23 1997-02-21 Mandigt præventionsimplantat DK0881891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/606,063 US5733565A (en) 1996-02-23 1996-02-23 Male contraceptive implant
PCT/US1997/002798 WO1997030656A1 (en) 1996-02-23 1997-02-21 Male contraceptive implant

Publications (1)

Publication Number Publication Date
DK0881891T3 true DK0881891T3 (da) 2005-05-23

Family

ID=24426375

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97907788T DK0881891T3 (da) 1996-02-23 1997-02-21 Mandigt præventionsimplantat
DK04022014T DK1488784T3 (da) 1996-02-23 1997-02-21 Svangerskabsforebyggende implantat til mænd

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04022014T DK1488784T3 (da) 1996-02-23 1997-02-21 Svangerskabsforebyggende implantat til mænd

Country Status (12)

Country Link
US (1) US5733565A (es)
EP (2) EP0881891B1 (es)
JP (1) JP2000505419A (es)
AT (2) ATE344018T1 (es)
AU (1) AU1969697A (es)
BR (1) BR9707637A (es)
CA (1) CA2243274C (es)
DE (2) DE69732176T2 (es)
DK (2) DK0881891T3 (es)
ES (2) ES2274367T3 (es)
PT (2) PT1488784E (es)
WO (1) WO1997030656A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6767902B2 (en) * 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US5952319A (en) 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
NZ331201A (en) * 1998-07-30 2001-02-23 Bomac Lab Ltd Slow release implants comprising an insoluble polymeric material in the form of a porous network containing vitamin B12 dispersed within
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
EP2561860B1 (en) * 2002-05-31 2018-02-28 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
FR2842421B1 (fr) * 2002-07-16 2004-10-15 Besins Int Belgique Nouvelles compositions pharmaceutiques a base d'inhibiteurs de la 5-alpha-reductase et leurs utilisations
WO2004016083A1 (ja) * 2002-08-19 2004-02-26 Nagoya Industrial Science Research Institute 球脊髄性筋萎縮症の病態を再現する非ヒト動物、及び球脊髄性筋萎縮症治療剤
AU2004228017C1 (en) 2003-03-31 2010-06-03 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
JO2492B1 (en) 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
JP2007502866A (ja) * 2003-05-30 2007-02-15 タイタン ファーマシューティカルズ インコーポレイテッド ナルメフェンの持続的放出のための移植可能ポリマー装置
US20060093639A1 (en) * 2004-10-29 2006-05-04 Starkebaum Warren L Method and device for destroying body tissue
AU2006259368A1 (en) * 2005-06-15 2006-12-28 Hydra Biosciences, Inc. Modulators of sperm hypermotility and uses thereof
ES2699200T3 (es) 2010-03-16 2019-02-07 Titan Pharmaceuticals Inc Dispositivos implantables heterogéneos de administración de fármacos
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
US10967122B2 (en) 2015-08-07 2021-04-06 Massachusetts Institute Of Technology Subcutaneous drug delivery device with manual activation and deactivation of drug release
US11690807B2 (en) * 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP3801378A4 (en) 2018-05-24 2022-02-23 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4451253A (en) * 1980-12-18 1984-05-29 Harman Sherman M Means and method for administering medicinals
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
DE19975054I2 (de) * 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) * 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device

Also Published As

Publication number Publication date
WO1997030656A1 (en) 1997-08-28
ES2274367T3 (es) 2007-05-16
DE69736911D1 (de) 2006-12-14
PT881891E (pt) 2005-04-29
EP0881891A4 (en) 2000-02-02
EP1488784A1 (en) 2004-12-22
CA2243274C (en) 2003-07-22
EP1488784B1 (en) 2006-11-02
BR9707637A (pt) 1999-07-27
DE69732176D1 (de) 2005-02-10
DK1488784T3 (da) 2007-03-05
PT1488784E (pt) 2006-12-29
DE69736911T2 (de) 2007-06-14
CA2243274A1 (en) 1997-08-28
ATE286370T1 (de) 2005-01-15
JP2000505419A (ja) 2000-05-09
EP0881891A1 (en) 1998-12-09
US5733565A (en) 1998-03-31
ES2236793T3 (es) 2005-07-16
ATE344018T1 (de) 2006-11-15
EP0881891B1 (en) 2005-01-05
DE69732176T2 (de) 2006-05-11
AU1969697A (en) 1997-09-10

Similar Documents

Publication Publication Date Title
DK0881891T3 (da) Mandigt præventionsimplantat
BR0010869A (pt) Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável
AU1369297A (en) Medical implant
DE68928897D1 (de) Verfahren und system zur empfängnisverhütung
HK1035335A1 (en) Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents p romoting the healing of wounds, to the upper respiratory tract and/or the ear
NO982815L (no) Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet
IL133762A0 (en) Transdermal therapeutic system (tts) for the administration of levonorgestral
CA2276587A1 (en) Silicone core long term androgen delivery implant
BG104250A (en) Levosimendan-containing composition for peroral administration
SG47451A1 (en) Implantable therapy system
AU1703101A (en) Ophthalmologic implant
EP0873751A3 (en) Pharmaceutical product for application to uterus mucosa
GB9905663D0 (en) Iodine preparation composition
EP0365613A4 (en) Combination of tobramycin and steroids for topical ophthalmic use
AU3401093A (en) Therapeutic agent for threatened abortion
Rosen Results of mobilization of fixed stapedial foot plate in otosclerotic deafness
DK561989A (da) Fokalt ophthalmisk praeparat som indeholder en kombination af tobramycin og steroider
UA30149A (uk) Спосіб хірургічного лікування багаторазово рецидивуючих пахових герній
UA29005A (uk) Спосіб лікування трофічних виразок нижніх кінцівок
GEU2002905Y (en) Externally Used Drug Formulation
TH55261B (th) การใช้ไบโอเจนิคอีสโตรเจนซัลฟาเมทในการรักษาการทดแทนฮอร์โมน
UA10771A (uk) Спосіб профілактики післяопераційhих ускладhеhь після екстракції катаракти з імплаhтацією кришталика
TW324663B (en) Interferon-ω(IFN-ω) as anti-HIV (human immune deficiency virus) agent
NO984725L (no) Depot-antiprogestin-behandling
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору